High-cost Drugs

The UK plans to boost its spending on expensive cancer drugs by around £160 million ($264 million) over the next two years, increasing its outlay from £200 million a year to £280 million per year, but the government also wants to increase its scrutiny of how well these drugs work for the cost.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.